TY - JOUR
T1 - Cilengitide in bevacizumab-refractory high-grade glioma
T2 - Two case reports and critical review of the literature
AU - Lombardi, Giuseppe
AU - Zustovich, Fable
AU - Farina, Patrizia
AU - Polo, Valentina
AU - Farina, Miriam
AU - Puppa, Alessandro Della
AU - Bertorelle, Roberta
AU - Gardiman, Marina Paola
AU - Berti, Franco
AU - Zagonel, Vittorina
PY - 2012/8
Y1 - 2012/8
N2 - High-grade gliomas (HGG) are aggressive and highly vascularized brain tumours. Despite multimodality therapy including surgery, radiation therapy and in many cases temozolomide chemotherapy, the prognosis is dismal. Salvage therapies following progression after radiation therapy and chemotherapy have historically yielded disappointing results. Bevacizumab is an interesting antiangiogenic drug used as a second-line treatment but although most patients benefit, essentially all patients ultimately progress. Moreover, some clinical studies have documented low activity of a second attempt at vascular endothelial growth factor pathway inhibition after failure of a first. The use of another drug with a different angiogenic pathway inhibition may probably result in a higher activity. Here, we describe, to our knowledge for the first time, the activity and safety of cilengitide, an agent with a different antiangiogenic and anti-invasive activity, administered in two bevacizumab-refractory patients with HGG. In addition, we present a rapid review of the activity of cilengitide in HGG.
AB - High-grade gliomas (HGG) are aggressive and highly vascularized brain tumours. Despite multimodality therapy including surgery, radiation therapy and in many cases temozolomide chemotherapy, the prognosis is dismal. Salvage therapies following progression after radiation therapy and chemotherapy have historically yielded disappointing results. Bevacizumab is an interesting antiangiogenic drug used as a second-line treatment but although most patients benefit, essentially all patients ultimately progress. Moreover, some clinical studies have documented low activity of a second attempt at vascular endothelial growth factor pathway inhibition after failure of a first. The use of another drug with a different angiogenic pathway inhibition may probably result in a higher activity. Here, we describe, to our knowledge for the first time, the activity and safety of cilengitide, an agent with a different antiangiogenic and anti-invasive activity, administered in two bevacizumab-refractory patients with HGG. In addition, we present a rapid review of the activity of cilengitide in HGG.
KW - angiogenesis
KW - bevacizumab
KW - cilengitide
KW - high-grade glioma
KW - recurrent glioma
UR - http://www.scopus.com/inward/record.url?scp=84863563759&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84863563759&partnerID=8YFLogxK
U2 - 10.1097/CAD.0b013e3283520e2c
DO - 10.1097/CAD.0b013e3283520e2c
M3 - Article
C2 - 22382388
AN - SCOPUS:84863563759
VL - 23
SP - 749
EP - 753
JO - Anti-Cancer Drugs
JF - Anti-Cancer Drugs
SN - 0959-4973
IS - 7
ER -